Video

Episode 13 - Treatment Challenges for Progressive Disease

Because there aren’t treatment options available for the management of progressive multiple sclerosis (MS), Patricia K. Coyle, MD, explains the challenges clinicians are faced with when treating patients who transition into a progressive stage of the disease.

Dr Coyle and Leslie Fish, PharmD, explain that although the topic of when to end therapy for patients who transition into a worsening stage is controversial, it is necessary to make personalized treatment decisions.

Dr Fish further explains how the rising costs of agents for the treatment MS further complicate management of MS and affect a clinician’s decision about when to begin or end therapy for a patient.


Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Cathy Eng, MD, FACP, FASCO
Leigh Maria Ramos-Platt, MD
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo